Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. [electronic resource]
Producer: 20040520Description: 4368-75 p. digitalISSN:- 1078-0432
- Adaptor Proteins, Signal Transducing
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Base Pair Mismatch
- Carcinoma, Squamous Cell -- drug therapy
- Carrier Proteins
- Cisplatin -- administration & dosage
- Combined Modality Therapy
- Down-Regulation
- Doxorubicin -- administration & dosage
- Esophageal Neoplasms -- drug therapy
- Female
- Fluorouracil -- administration & dosage
- Humans
- Immunoenzyme Techniques
- Lymphatic Metastasis
- Male
- Middle Aged
- MutL Protein Homolog 1
- Neoadjuvant Therapy
- Neoplasm Proteins -- metabolism
- Nuclear Proteins
- Postoperative Period
- Preoperative Care
- Prognosis
- Survival Rate
- Tumor Suppressor Protein p53 -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.